Clinical Trial ResultsResponse rates in HELIOS came in below the approved anti-VEGFs, which is viewed as an overreaction considering axpaxli’s differentiated durability profile and management’s commitment to Phase 3.
Investor ExpectationsSome signs of efficacy, missing investor expectations, but caution is advised in reading too much into the small study.
Stock PerformanceOCUL shares are down ~12% after response rates in HELIOS came in below the approved anti-VEGFs.